Worth reading
40Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
38.4
Year-on-year change in operating profit (%)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Summary of Q&ASecond quarter (interim period) of the fiscal year ending December 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥3,376 million-7.9%
Operating profit¥345 million-38.4%
Full-year earnings forecast
Net Sales
¥7,500 million
Operating profit
¥950 million
Ordinary income
¥935 million
Profit attributable to owners of the parent
¥580 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales45.0%
Operating profit36.3%
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
- Issues Full-year forecast / Answer The full-year forecast remains unchanged. First-half revenue progress was 45.0%, and operating profit progress was 36.3%. In the second half, the Company will rebuild its earnings base through recurring revenue and the launch of new partnership projects.
- Issues Factors behind the first-half decline in revenue and profit / Answer The main factors were lower Web advertising rates, the absence of one-time revenue, and revised contract terms. Recurring businesses in education and medical aesthetics continued to expand.
- Issues Recovery measures for the second half / Answer Recurring revenue from the medical aesthetics and education businesses, new channels for the advertising games business, and the new pipeline in the solutions business will serve as growth drivers.
- Issues Business Portfolio Transformation / Answer The gross profit contribution of industry-specific businesses rose from 14.7% in the second quarter of 2022 to 38.7% in the second quarter of 2026.
- Issues Use of AI / Answer The Company is developing AI voice medical records, AI management analysis, and question-generation and grading support tools. The AI grading solution for essay questions is scheduled to launch in spring 2027.
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Decline in flow-based revenue in part of the media business due to lower Web advertising rates
- Absence of one-time revenue from beauty-related coupon products
- Revised contract terms in the solutions business
The company identifies the factors but does not state the amount attributable to each one.
New initiatives
- Adding AI voice medical records and expanding AI features for Kireipass Connect
- Launch of Koeteco Study
- Development of an AI grading solution for essay questions with a major textbook publisher
- Partnerships with new media and other partners in the advertising games business
- Launch of 5 new pipeline projects for the GMOリピータス customer-retention platform
Key KPIsA metric the company considers important as a management benchmark.
- Gross profit contribution of industry-specific businesses (education and medical aesthetics)38.7%
- GMOリピータス customer-retention platform: new pipeline5 Engagements
Unit price and quantity metricsThese figures show sales broken down by price and volume.
The Company intends to increase revenue per contracted clinic in the medical aesthetics field and expand the number of contracted clinics; figures are Not disclosed| Item | Details |
|---|---|
| Document type | Summary of Q&A |
| Fiscal Period Covered | Second quarter (interim period) of the fiscal year ending December 2026 |
| Net Sales | ¥3,376 million (YoY -7.9%) |
| Operating profit | ¥345 million (YoY -38.4%) |
| Full-year earnings forecast | Net Sales ¥7,500 million / Operating profit ¥950 million / Ordinary income ¥935 million / Profit attributable to owners of the parent ¥580 million |
| Progress against full-year forecast | Net Sales 45.0% / Operating profit 36.3% |
| Breakdown of Factors Affecting the Change | Factors Decline in flow-based revenue in part of the media business due to lower Web advertising rates / Amount Not disclosed, Factors Absence of one-time revenue from beauty-related coupon products / Amount Not disclosed, Factors Revised contract terms in the solutions business / Amount Not disclosed |
| Key KPIs | Indicator name Gross profit contribution of industry-specific businesses (education and medical aesthetics) / Value 38.7% / Year on year against the same period last year Not disclosed, Indicator name GMOリピータス customer-retention platform: new pipeline / Value 5 Engagements / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | The Company intends to increase revenue per contracted clinic in the medical aesthetics field and expand the number of contracted clinics; figures are Not disclosed |
| Key points of the Q&A | Issues Full-year forecast / Answer The full-year forecast remains unchanged. First-half revenue progress was 45.0%, and operating profit progress was 36.3%. In the second half, the Company will rebuild its earnings base through recurring revenue and the launch of new partnership projects., Issues Factors behind the first-half decline in revenue and profit / Answer The main factors were lower Web advertising rates, the absence of one-time revenue, and revised contract terms. Recurring businesses in education and medical aesthetics continued to expand., Issues Recovery measures for the second half / Answer Recurring revenue from the medical aesthetics and education businesses, new channels for the advertising games business, and the new pipeline in the solutions business will serve as growth drivers., Issues Business Portfolio Transformation / Answer The gross profit contribution of industry-specific businesses rose from 14.7% in the second quarter of 2022 to 38.7% in the second quarter of 2026., Issues Use of AI / Answer The Company is developing AI voice medical records, AI management analysis, and question-generation and grading support tools. The AI grading solution for essay questions is scheduled to launch in spring 2027. |
| New initiatives | Adding AI voice medical records and expanding AI features for Kireipass Connect, Launch of Koeteco Study, Development of an AI grading solution for essay questions with a major textbook publisher, Partnerships with new media and other partners in the advertising games business, Launch of 5 new pipeline projects for the GMOリピータス customer-retention platform |
Items this document does not state (20)
Ordinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterSelf-assessment against the planSegment resultsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / Share
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Lower flow-based revenue in part of the media business due to declining Web advertising rates, the absence of one-time revenue from beauty-related coupon products that performed well in the previous fiscal year, and the impact of revised contract terms in the solutions business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.